Cancer Treatment News and Research

RSS

Medicare will still cover Avastin for breast cancer, despite revocation of FDA approval

The FDA announced that Avastin, while still approved for other cancers, is more harmful than helpful to breast cancer patients.

22 Nov 2011

USPTO to issue patent for CU's DCA to treat cancer

Viral Genetics reports that a patent under which it is exclusively licensed will be granted for using a compound known as DCA to treat cancer.

21 Nov 2011

FDA grants HDE marketing approval for BSD-2000 Hyperthermia System to treat cervical cancer

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has obtained Humanitarian Device Exemption (HDE) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) from the U.S. Food and Drug Administration.

21 Nov 2011

Cancer Research UK initiates recruitment for Stratified Medicine Programme

Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the NHS to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies.

21 Nov 2011

FDA revokes approval of Avastin for breast cancer

The commissioner of the Food and Drug Administration on Friday revoked the approval of the drug Avastin as a treatment for breast cancer, ruling in an emotional issue that pitted the hopes of some desperate patients against the statistics of clinical trials.

19 Nov 2011

Cancer Research UK embarks on new initiative to unravel genetic secrets behind cancers

Unravelling the genetic secrets behind a range of cancers - from understanding how certain genes control cancer to determining how the disease evades treatment - is the aim of a new initiative from Cancer Research UK.

18 Nov 2011

Tikcro reports net loss of $1.0 million for third quarter 2011

Tikcro Technologies Ltd. today reported results for the third quarter and nine months ended September 30, 2011.

18 Nov 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Life Beyond Cancer's 12th annual retreat from November 18 to 20

Austin, Texas: Some 150 cancer survivors, health care providers and patient advocates will discover ways to inspire, empower and motivate those to a Life Beyond Cancer, November 18 to 20 at the Lakeway Resort and Spa.

17 Nov 2011

MDxHealth total revenues decrease 7% for third quarter 2011

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the third quarter and for the nine months ended September 30, 2011.

17 Nov 2011

Breakthrough in loading gold nanorods into cells could lead to new cancer treatment

Rice University chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell. The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.

17 Nov 2011

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

New potential target to slow breast cancer tumor progression and metastasis

A new potential target to slow breast cancer tumor progression and metastasis has been identified by a team of researchers led by Dr. Richard Kremer from the Research Institute of the McGill University Health Centre.

11 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Researchers plan joint clinical trials of new cancer treatments, personalized therapies

The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.

9 Nov 2011

Semtech to donate $25,000 for new UCLA cancer treatment center

Semtech Corporation, a leading supplier of analog and mixed-signal semiconductors, today announced it will contribute $25,000 to the UCLA Hospital System toward the development of a new treatment center at the Ronald Reagan UCLA Medical Center for teen and young adult cancer patients.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

CWRU to establish umbrella program for integrative oncology

Case Western Reserve University School of Medicine is honored to announce gifts to establish the inaugural Parker Hannifin - Helen Moss Cancer Research Foundation Professorship in Integrative Oncology. This professorship will establish the School of Medicine and its affiliate hospitals as national leaders in teaching, research, and patient care in the field of integrative oncology.

8 Nov 2011

DSS VistA Chemotherapy Manager goes live at San Francisco VA Medical Center

DSS, Inc., a leading provider of software development, integration, project management, implementation and support of VistA, today announced that its customized VistA Chemotherapy Manager (VCM) system is now live and in production at the San Francisco VA Medical Center.

7 Nov 2011